BRPI0922985A2 - vetor de direcionamento (homing) de receptor de fator de crescimento epidérmico (egfr), método para tratamento de câncer caracterizado por células superexpressando egfr, composição farmacêutica para administração sistêmica. - Google Patents

vetor de direcionamento (homing) de receptor de fator de crescimento epidérmico (egfr), método para tratamento de câncer caracterizado por células superexpressando egfr, composição farmacêutica para administração sistêmica.

Info

Publication number
BRPI0922985A2
BRPI0922985A2 BRPI0922985A BRPI0922985A BRPI0922985A2 BR PI0922985 A2 BRPI0922985 A2 BR PI0922985A2 BR PI0922985 A BRPI0922985 A BR PI0922985A BR PI0922985 A BRPI0922985 A BR PI0922985A BR PI0922985 A2 BRPI0922985 A2 BR PI0922985A2
Authority
BR
Brazil
Prior art keywords
egfr
pharmaceutical composition
growth factor
factor receptor
epidermal growth
Prior art date
Application number
BRPI0922985A
Other languages
English (en)
Inventor
Alexander Levitzki
Alexei Shir
Original Assignee
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co filed Critical Yissum Res Dev Co
Publication of BRPI0922985A2 publication Critical patent/BRPI0922985A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Information Transfer Between Computers (AREA)
  • Peptides Or Proteins (AREA)
BRPI0922985A 2008-12-22 2009-12-22 vetor de direcionamento (homing) de receptor de fator de crescimento epidérmico (egfr), método para tratamento de câncer caracterizado por células superexpressando egfr, composição farmacêutica para administração sistêmica. BRPI0922985A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13969808P 2008-12-22 2008-12-22
PCT/IL2009/001210 WO2010073247A2 (en) 2008-12-22 2009-12-22 Egfr-homing double-stranded rna vector for systemic cancer treatment

Publications (1)

Publication Number Publication Date
BRPI0922985A2 true BRPI0922985A2 (pt) 2016-10-04

Family

ID=42104511

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0922985A BRPI0922985A2 (pt) 2008-12-22 2009-12-22 vetor de direcionamento (homing) de receptor de fator de crescimento epidérmico (egfr), método para tratamento de câncer caracterizado por células superexpressando egfr, composição farmacêutica para administração sistêmica.

Country Status (20)

Country Link
US (2) US9006406B2 (pt)
EP (3) EP2379597B8 (pt)
JP (1) JP2012513210A (pt)
CN (1) CN102325794A (pt)
AU (1) AU2009332522A1 (pt)
BR (1) BRPI0922985A2 (pt)
CA (1) CA2748125A1 (pt)
CY (1) CY1123371T1 (pt)
DK (2) DK3098239T3 (pt)
ES (2) ES2602753T3 (pt)
HR (1) HRP20192317T1 (pt)
HU (1) HUE047759T2 (pt)
IL (1) IL213739A0 (pt)
LT (1) LT3098239T (pt)
MX (1) MX2011006720A (pt)
PL (1) PL3098239T3 (pt)
PT (1) PT3098239T (pt)
SI (1) SI3098239T1 (pt)
SM (1) SMT202000038T1 (pt)
WO (1) WO2010073247A2 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201406208QA (en) * 2012-05-03 2014-11-27 Janssen Sciences Ireland Uc Polyinosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections
JP6103832B2 (ja) 2012-06-25 2017-03-29 Hoya株式会社 Ｅｇｆｒ結合性ペプチド
US9431064B2 (en) * 2012-11-02 2016-08-30 Taiwan Semiconductor Manufacturing Company, Ltd. Memory circuit and cache circuit configuration
US10796320B2 (en) * 2013-12-23 2020-10-06 Mastercard International Incorporated Systems and methods for passively determining a ratio of purchasers and prospective purchasers in a merchant location
US10278991B2 (en) 2014-05-14 2019-05-07 Targimmune Therapeutics Ag Polyethyleneimine polyethyleneglycol vectors
EP3274840A4 (en) * 2015-03-27 2018-12-26 Intel Corporation Dynamic cache allocation
PT3319587T (pt) * 2015-11-17 2019-11-20 Bioncotech Therapeutics S L Nova composição farmacêutica que compreende partículas compreendendo um complexo de um polirribonuleótido de cadeia dupla e uma polialquilenoimina
GB201601868D0 (en) * 2016-02-02 2016-03-16 Lytix Biopharma As Methods
CN105669964B (zh) * 2016-03-04 2017-11-21 博瑞生物医药（苏州）股份有限公司 卵巢癌特异靶向的生物可降解双亲性聚合物、由其制备的聚合物囊泡及应用
WO2018042411A1 (en) * 2016-09-04 2018-03-08 Alex Levitzki Management And Holdings, Ltd. Chimeric proteins for targeting dsrna
JP2020520368A (ja) * 2017-05-17 2020-07-09 ビオンコテック セラピューティクス エセ．エレ 二本鎖ポリリボヌクレオチドとポリアルキレンイミンとの複合体を含む粒子を含む新規な医薬組成物
EP3688008A1 (en) * 2017-09-27 2020-08-05 TargImmune Therapeutics AG Castration resistant prostate cancer
KR20210087949A (ko) 2018-11-01 2021-07-13 알파 타우 메디컬 리미티드 종양내 알파-방출체 방사선 및 세포내 병원체에 대한 세포질 센서의 활성화
SG11202109274TA (en) * 2019-04-03 2021-10-28 Targimmune Therapeutics Ag Immunotherapy for the treatment of cancer
WO2020263770A1 (en) * 2019-06-24 2020-12-30 North Carolina State University Nucleic acid compositions including a polyalkyleneimine-alkoxylene polymer and methods of making and using the same
WO2020263776A1 (en) * 2019-06-24 2020-12-30 North Carolina State University Nucleic acid compositions including a polyalkyleneimine-alkoxylene polymer and methods of making and using the same
US10915418B1 (en) 2019-08-29 2021-02-09 Snowflake Inc. Automated query retry in a database environment
IL320618A (en) 2022-11-07 2025-07-01 Targimmune Therapeutics Ag Polyplexes of nucleic acids and targeted pairs containing polyethyleneimine and polyethylene glycol
WO2025238236A1 (en) 2024-05-16 2025-11-20 Targimmune Therapeutics Ag Polyplexes of nucleic acids and targeted conjugates comprising polyethyleneimine and polyethylene glycol

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004045491A2 (en) 2002-11-18 2004-06-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Targeted double stranded rna mediated cell killing
WO2006054129A1 (en) * 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
US7937291B2 (en) * 2009-04-22 2011-05-03 Visa U.S.A. Inc. Providing an announcement about transactions of a target merchant to a consumer

Also Published As

Publication number Publication date
MX2011006720A (es) 2011-10-06
LT3098239T (lt) 2020-02-10
HUE047759T2 (hu) 2020-05-28
PL3098239T3 (pl) 2020-04-30
CY1123371T1 (el) 2021-10-29
EP3098239B1 (en) 2019-10-23
US9006406B2 (en) 2015-04-14
US20120021006A1 (en) 2012-01-26
EP3098239A1 (en) 2016-11-30
CN102325794A (zh) 2012-01-18
WO2010073247A3 (en) 2010-08-19
ES2764396T3 (es) 2020-06-03
ES2602753T3 (es) 2017-02-22
AU2009332522A1 (en) 2011-08-11
EP3705493A1 (en) 2020-09-09
DK2379597T3 (en) 2016-12-05
SI3098239T1 (sl) 2020-03-31
JP2012513210A (ja) 2012-06-14
WO2010073247A2 (en) 2010-07-01
EP2379597B8 (en) 2016-11-30
EP2379597A2 (en) 2011-10-26
SMT202000038T1 (it) 2020-03-13
DK3098239T3 (da) 2020-01-20
CA2748125A1 (en) 2010-07-01
HRP20192317T1 (hr) 2020-03-20
PT3098239T (pt) 2020-01-15
EP2379597B1 (en) 2016-08-10
IL213739A0 (en) 2011-07-31
US20120330998A1 (en) 2012-12-27

Similar Documents

Publication Publication Date Title
HUE037645T2 (hu) Rák kezelésére alkalmas 2.(2,4,5-helyettesített-anilino)pirimidin származékok mint EGFR modulátorok
BRPI0816014A8 (pt) anticorpo humano monoclonal isolado, composição, conjugado anticorpo-molécula parceiro, mólecula isolada de ácido nucléico, vetor de expressão, célula hospedeira, método para preparar um anticorpo anti-mesotelina, método de inibição do crescimento de uma célula tumoral expressando a mesotelina, método de tratamento do câncer em um indivíduo, anticorpo anti-mesotelina isolado, e método de inibir o crescimento de uma célula expressando a mesotelina
BRPI0808104A2 (pt) Métodos para preparar e para produzir um polipeptídeo, polipeptídeo, sequência de ácido nucleico isolada, construção de ácido nucleico, vetor de expressão recombinante, e, célula hospedeira recombinante
BRPI0814781A2 (pt) Proteína, sequência de ácido nucleico, método para a produção de ácido itacônico, vetor, célula hospedeira, e, uso de um ácido cis-aconítico
BRPI0922475A2 (pt) composto, composição farmacêutica , método para tratar câncer, e, uso de um composto.
IL208877A0 (en) Systems, methods and compostions for optical stimlation of target cells
BRPI0909198A2 (pt) composto antifolato, composto, método para preparar um composto antifolato, composição farmacêutica, método para tratar
AU2009301431A8 (en) Bispecific anti-VEGF/anti-ANG-2 antibodies
WO2008039969A3 (en) Cancer vaccines and vaccination methods
BRPI0918768A2 (pt) composições de anticorpo recombinante de anti-receptor do fator de crescimento epidérmico.
WO2009107121A8 (en) Medical apparatus and method for attaching a suture to a bone
CL2007001040A1 (es) Proceso para la preparacion de antagonista de la sustancia p derivado de acil-amino-alquilen-amida.
BRPI0905076A2 (pt) Polipeptídeo, anticorpo, região variável, cadeia pesada ou cadeia leve, gene, vetor, célula hospedeira, método para produzir o referido polipeptídeo, e composição farmacêutica compreendendo o mesmo
BRPI0813242A2 (pt) Proteína de ligação a antígeno isolada, ácido nucléico isolado, vetor, célula hospedeira isolada, método para a produção de uma proteína de ligação a antígeno, e, composição.
BRPI0916964A2 (pt) polipetídeo, anticorpo, ácido nucléico, vetor, célula hospedeira, método para produzir um polipeptídeo, composição e uso do polipeptídeo
BRPI0823030A2 (pt) Sistema de elevador, e, método para fazer um sistema de elevador.
BRPI0922566A2 (pt) polimorfo cristalino, composição farmacêutica, composto, e, métodos para preparar um composto, e para tratar uma doença.
BRPI1011144A2 (pt) proteína precursora, sequência de ácido nucleico, cassete de expressão, vetor recombinante, método para produzir um peptídeo desejado, e, uso de um peptídeo anfifílico.
LT3098239T (lt) Į egfr nukreipiamas dvigrandis rnr vektorius, skirtas sisteminiam vėžio gydymui
WO2013023043A3 (en) Treatment of advanced solid tumors using combination of anti-erbb3 immunotherapy and selected chemotherapy
WO2012138715A3 (en) Small molecule inhibitors of xbp1 splicing
WO2008051539A3 (en) Processes for preparing palonosetron salts
BRPI0813743A2 (pt) Método para produzir trombina humana recombinante, trombina recombinante, composição farmacêutica, sequência de dna isolada, vetor, sequência de aminoácido, e, célula hospedeira.
BRPI1009241A2 (pt) anticorpo monoclonal anti-rhd, ácido nucleico, vetor de expressão, célula hospedeira, método para produção de um anticorpo, composição farmacêutica.
UY31013A1 (es) Metodos para prepar compuestos basados en imidazol

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]